Practical digitization at reasonable costs

Why pharma projects are frequently delayed—and how external experts can solve this problem

Content item image
George Station Master

  1. Why pharma projects are often delayed—and how external experts can solve this problem

Although pharma companies invest heavily in strategy, planning, and regulatory compliance, persistent implementation problems keep occurring, specifically in these areas:

  1. Technology transfer
  2. Validation
  3. Manufacturing

Here are some customer issues from our practice over the past twelve months:

  • The completion of a transfer project is delayed by several months.
  • A process validation fails completely, making a complete repetition necessary. This happens even though the topic was previously discussed intensively for months.
  • The times for batch release vary inexplicably. This leads to high fluctuations in inventory and cash flow.
  • Collaboration with the contract manufacturing organization (CDMO) is characterized by reactive measures. Manufacturing at the contract manufacturer has taken on a life of its own.

If these problems sound familiar to you:
You are not alone. These problems occur frequently and are not strategic problems, but Implementation problems.

  1. Pharma projects fail, not because they are too complex

You fail because the execution collapses under pressure. The immediate consequences are then:

  • elevated GMP risk
  • delayed product availability and the associated threat of lost revenue
  • internal escalation to top management level to solve the problem
  • Points of attack in audits and inspections

A delayed pharmaceutical project is not simply a project that takes a few days or weeks longer. The delay is not neutral. The risk does not increase linearly over time. This means that a delay of 10–20 % results in a risk increase of far more than 10–20 % for GMP compliance and for revenue.

The real reasons for the delay in pharmaceutical projects

To improve the implementation of pharmaceutical projects, it is crucial to understand,
where these delays actually come from. In most cases that we see in our practice,
the roots of the problems do not lie in the technical part, but rather in the operational implementation.

This happens even though the technical implementation, including the planning software to be used, is primarily discussed in the run-up to projects. However, the real reasons are different.

  1. Workload overload of the MSAT and QA teams

We very often see that the teams in MSAT and QA are overloaded. In the GMP environment in which pharmaceutical companies operate, many projects have a technical or regulatory background. Therefore, these two departments must handle them.

These teams are responsible for, among other things:

  • Process validations
  • Technology transfers
  • GMP compliance
  • Batch release

In addition to their standard tasks, they are also involved in high-priority projects.

The result is then:

Reactive decision-making means that decisions are made only after the deadline has passed and not as early as possible. Problems are addressed late and therefore also solved late.

  • Although pharmaceutical companies invest heavily in strategy, planning, and regulatory compliance, persistent implementation problems keep occurring, especially in these areas.
  • The focus is not on the critical steps in the process flow, but on the parts with the greatest delay.

This is visible, but cannot be turned off.

  1. Lack of coordination between MSAT, QA, and Manufacturing

Many delays in pharmaceutical manufacturing and its projects are rooted in a lack of, or failure to perform, alignment between different functions. Very rarely is it genuinely about scientific or technical challenges.

Typical problem patterns are, for example:

  • Processes are changed or realigned without coordination with QA.
  • Limitations in the manufacturing process are identified too late.
  • Current manufacturing is no longer completely compliant with the dossier.

This leads to these symptoms:

  • Individual processes sometimes require rework or lead to high scrap rates.
  • Process validations fail.
  • Delays in batch release.

Most delays in the pharmaceutical industry are not caused by technical errors or defects. They are actually coordination problems between key departments and functions.

  1. Lack of control over contract manufacturers and third-party operations„

Outsourcing manufacturing or technology transfer to a contract development and manufacturing organization (CDMO) is usually done to reduce production costs. Companies often overlook the fact that this increases the complexity of coordination.

Why is that?

Outsourcing production does not mean outsourcing responsibility. Common problems in working with contract manufacturers include, for example:

  • There is a lack of transparency regarding how well or poorly the project is actually progressing on the contract manufacturer's side.
  • The expectations of both sides are different and uncoordinated; this also applies to the schedules for project implementation.
  • The risks to quality and compliance are identified late in the project.

Without strong management and good coordination of third parties, pharmaceutical companies easily lose control over manufacturing and batch release at the contract manufacturer. This is critical, as the customer continues to bear product responsibility.

  1. Validation and bottlenecks in documentation

Delayed validations are often a significant reason for the delay of transfer projects. Often we see the causes in these areas:

  • Insufficient coordination before starting the validation („silo mentality“).
  • QA joins the process late.
  • Gaps in the documentation are only discovered shortly before or during validation.
  • (for example, discrepancies between actual manufacturing and the process described in the dossier).

The entire GMP schedule is falling behind and needs to be postponed (for example, the submission date for dossier variations).

In many cases, validation is slow not because of high complexity or technical difficulties, but because inter-departmental coordination works poorly or happens too late. A common phenomenon is extremely long review cycles for validation documents, which sometimes drag on for months.

  1. Inefficient consultants

When projects go off the rails, organizations hire external consultants. But with traditional consulting, they often bring in additional problems:

  • The coordination becomes even more complex, especially when relatively inexperienced consultants are active.
  • There are even more levels of communication that require synchronization.
  • The implementation teams are staffed with inexperienced personnel.
  • This often slows down decision-making even further, instead of speeding it up.
  • The more rigidly consulting firms apply their respective model, the slower the implementation becomes.

  1. The hidden costs of delayed pharma projects

Delayed pharma projects are often considered a purely planning problem that can be easily fixed by a change in the schedule. In reality, however, they have far-reaching operational and strategic consequences and financial impacts:

  1. A delayed product launch not only causes high consequential costs, but also leads to missing revenues that were already planned.
  1. Operating costs increase because two parallel structures are operated during the delay.
  1. Already allocated resources require reallocation, leading to higher costs and delays in other projects.
  1. Regulatory risks: Unplanned deviations must be corrected and processed as such. This creates potential vulnerabilities in future inspections and thus increases the GMP risk.

Deviations require complex documentation and coordination; these are often points of vulnerability during inspections and audits. Every unplanned activity that must be documented and improved increases the risk of audit issues.

Organizational impacts

  • Increased internal pressure within the implementation team.
  • Problems escalate to the highest management level and must be dealt with there.
  • Trust in the project manager is being undermined.
  • Operational inefficiency
  • Work steps must be repeated.
  • Increased effort for deviation management.
  • Project delays also affect other projects because resources are tied up
  • Every additional delay significantly increases the risk.
  • The cost of inaction is always higher than the cost of intervention.

  1. Why the traditional solutions
    approaches in pharmaceuticals
    projects are not working

When pharma projects fall behind schedule, organizations typically deploy these countermeasures:

  • Allocate more resources to the delayed project (and withdraw them from other projects)
  • More precise and detailed reporting („micromanagement“)
  • To hire a large consulting firm

These approaches mostly do not work because they do not solve the root of the problem:

  • There is a lack of clarity in the implementation, as well as a sense of accountability.
  • More people lead to more complexity and coordination effort.
  • More reporting leads to less implementation, if only for lack of time.
  • A more complex structure leads to slower decisions.

The problem is not the allocation of resources – it is the implementation.

  1. How external experts ex
    delays in pharmaceuticals
    fix projects quickly

  1. How external experts quickly resolve delays in pharma projects

Highly effective, external experts do not work as consultants. They operate as an integrated decision-making level within pharmaceutical projects.

Rapid identification of bottlenecks

Experienced pharma consultants quickly identify:
where the implementation is blocked
where unclear decisions are made
where risks accumulate

Because of their experience, they only need days for this and not months.

Practical experience in transfer implementation. Unlike traditional consulting firms, external experts have a different impact:

  1. You drive implementations proactively.
  2. You assume responsibility for the most important key processes.
  3. You directly support departments with resource problems such as MSAT, QA, and manufacturing.
  4. This reduces the pressure on internal teams and accelerates processes immediately.

Coordination between different departments and functions

Effective external experts bridge differing views in departments such as:

  • MSAT
  • QA, QC
  • Manufacturing and production
  • CDMO

They achieve this because they themselves used to work operationally in these functions and departments. This coordination reduces scrap and repeated processes and ensures consistent decision-making.

Control over CMOs and Third Party Management„

Independent consultants with experience offer the following benefits:

  • A clear insight into how contract manufacturers handle projects
  • Coordination and clarification of the differing views and goals
  • Early identification of risks

This transforms outsourcing projects from reactive project management
into an actively managed project.

Build in GMP compliance from the start

Instead of discussing compliance late, external experts act like this:

  • You integrate the GMP requirements directly into the decisions. You link the documentation with the actual process and its progress.
  • You ensure audit compliance throughout the entire project.
  • This is how to avoid problems in process validation or during
  • qualifications and reduces audit risk.
What makes external experts effective in pharma projects? By far not all consultants deliver Results. The difference lies in the ability to execute. The key characteristics of highly effective implementation specialists:
  • Practical experience in implementation in a GMP environment
  • Experience in MSAT, Manufacturing, Quality Department, Procurement, CMO Management
  • The Ability, to get up to speed quickly and generate results
  • Lean and agile without unnecessary overhead
  • Independence of contract manufacturers and suppliers

The value does not lie in additional capacity. It comes from restoring clear execution.

When should pharmaceutical companies bring in external support? Timing is crucial. Many organizations wait until projects are in an almost unsalvageable mess before they act.

Pay attention to these warning signs:

  • Transfer delays
  • Recurring issues with process validations, including delays
  • Increased number of deviations
  • Contract manufacturers, CMOs or CDMOs are acting as if they are out of control
  • Overload of critical departments or functions such as MSAT or QA teams
  • Regulatory issues, for example during inspections or audits

If you observe several of these warning signs, it is high time to take action.

If your current projects show these patterns, you are already experiencing delays and risking further ones. In most cases, these problems can be corrected, but only if implementation bottlenecks are found quickly and fixed directly.

The advantage of fast action

On the other hand, a delayed intervention leads to:
Increased costs
Additional attack vectors during inspections and audits
A significantly more complicated restoration

Execution determines success.

Many pharma companies do not lack expertise.
You lack the ability to execute under pressure.

Projects are successful when:

  • decisions are made and implemented quickly,
  • Teams act in a coordinated manner
  • and the implementation proceeds in a controlled manner, not reactively.
  • In many cases, this requires external support from

experienced implementation experts who work within the process rather than outside it.

Stabilize delayed pharma projects before they become compliance risks

Most delayed pharmaceutical projects can be turned around.
However, not within the structure that caused these delays.

An implementation-focused external approach can:

  • Identify bottlenecks quickly and independently
  • Restore control
  • Reduce the risk
  • Accelerate schedules
Content item image

Dr Georg Astl

Dr Georg Astl is the founder of Eoswiss Pharma. He is the author of numerous specialized articles and a speaker at professional events.

Frequently Asked Questions (FAQ)

How can pharmaceutical projects be implemented faster?

Pharma projects can be implemented faster if implementation bottlenecks are identified early and specifically resolved. Crucial factors are clear responsibilities, close coordination between MSAT, QA, and production, as well as active management of CDMOs. As a result, delays in technology transfer and validation can be significantly reduced.

Why are GMP projects delayed so often?

GMP projects are frequently delayed by the overload of MSAT and QA teams, a lack of alignment between departments, and insufficient control over external partners such as CDMOs. These factors lead to delays in technology transfer, validation, and batch release while simultaneously increasing compliance risk.

How do you reduce GMP risks in projects?

GMP risks can be reduced if quality requirements are integrated into implementation from the outset. This includes close coordination between QA, MSAT, and manufacturing, as well as consistent documentation along the actual process. Early identification of deviations prevents issues during audits and inspections.

How do you improve collaboration with CDMOs?

Collaboration with CDMOs is improved through clear governance structures, transparent communication, and active management of external partners. It is important that progress, risks, and responsibilities are continuously monitored to avoid delays and quality issues.

When should external experts be used in pharma projects?

External experts are useful when projects are delayed, validations fail, or internal teams are overburdened. They help to quickly identify bottlenecks, accelerate decisions, and bring projects back under control.

How can technology transfer in pharma be accelerated?

Technology transfer can be accelerated by clear process definitions, early alignment between MSAT, QA, and production, as well as structured management of CDMOs. The key is to identify risks early and manage them actively rather than acting reactively.